ArticleLaboratory investigation; a journal of technical methods and pathology2009
Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells.
Article in Laboratory investigation; a journal of technical methods and pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Targeted Delivery of CD34 Aptamer-Coupled Tocilizumab Microspheres for Effective Treatment of Thyroid-Associated Ophthalmopathy.Investigative ophthalmology & visual science · 2025Article
- Aptamer-Based Probes for Cancer Diagnostics and Treatment.Life (Basel, Switzerland) · 2022Review
- Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases.Molecules (Basel, Switzerland) · 2022Review
- Recent advances in aptamer-based targeted drug delivery systems for cancer therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Review
- Current Advances in the Development of Diagnostic Tests based on Aptamers in Parasitology: A Systematic Review.Pharmaceutics · 2020Review
- Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.International journal of molecular sciences · 2020Review
- Aptamer-based approaches forResearch in pharmaceutical sciences · 2020Review
- Article
- Silencing RORγt in Human CD4Scientific reports · 2019Article
- Idiosyncrasies of thermofluorimetric aptamer binding assays.BioTechniques · 2019Article
- Using an RNA aptamer probe for super-resolution imaging of native EGFR.Nanoscale advances · 2019Article
- Aptamers as Diagnostic Tools in Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Aptamer-based targeted therapy.Advanced drug delivery reviews · 2018Review
- Affinity capture of aflatoxin BMikrochimica acta · 2018Article
- Aptamers for CD Antigens: From Cell Profiling to Activity Modulation.Molecular therapy. Nucleic acids · 2017Review
- Aptamers: versatile molecular recognition probes for cancer detection.The Analyst · 2016Review
- Aptamer-Drug Conjugates.Bioconjugate chemistry · 2015Review
- Manipulating the in vivo immune response by targeted gene knockdown.Current opinion in immunology · 2015Review
- A Highlight of Recent Advances in Aptamer Technology and Its Application.Molecules (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Aptamers are small molecular ligands composed of short oligonucleotides that bind targets with high affinity. In contrast to antibodies, as synthetic oligonucleotides, aptamers have lower production costs and elicit no antigenic reactions. Therefore, aptamers are potential agents for disease diagnosis and treatment. In this study, we validate a fluorescently labeled RNA aptamer, which has been reported to bind specifically to mouse CD30 proteins in solution, for human CD30 protein recognition on intact cells. The aptamer probe was tested with cultured anaplastic large cell lymphoma and Hodgkin's lymphoma cells that express high levels of CD30. Flow cytometry and fluorescence microscopy showed specific and sensitive binding of the aptamer probe to CD30-expressing lymphoma cells at low concentrations (0.3 nM). Studies performed on multiple cell lines and nuclear cells from healthy donors confirmed that the CD30 aptamer and anti-CD30 antibody, the standard clinical probe, recognized the same set of cells. The potential application of multicolor flow cytometry analysis using the CD30 aptamer probe and antibodies was also shown. In conclusion, the developed CD30 aptamer probe could act as a replacement and/or a supplement for antibodies in the diagnosis of the CD30-expressing lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.